2,438 results match your criteria Sentinel Lymph Node Biopsy in Patients With Melanoma


Enhancing the prognostic role of melanoma sentinel lymph nodes through microscopic tumour burden characterization: clinical usefulness in patients who do not undergo complete lymph node dissection.

Melanoma Res 2018 Jul 17. Epub 2018 Jul 17.

Department of Plastic and Reconstructive Surgery, Regional Melanoma Referral Center and Melanoma & Skin Cancer Unit.

This study aimed to investigate the sentinel lymph node (SLN) tumour burden to predict the non-SLN positivity rate and the survival of melanoma patients to evaluate whether SLN microstaging could predict the prognosis, similar to what is currently performed by examining the lymph nodes excised by complete lymph node dissection. Of 1130 consecutive melanoma patients who underwent SLN biopsy, 226 were tumour-positive and 204 were included in this study. SLN metastases were classified on the basis of dimensional (Rotterdam) and topographic (Dewar) criteria either separately or combined. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/CMR.0000000000000481DOI Listing

Efficacy and reproducibility of lymphatics mapping technique with sentinel lymph node biopsy in melanoma.

Cir Cir 2019 ;87(2):241-246

Hospital Privado Universitario de Córdoba, Córdoba, Argentina.

Introduction: The study of the Sentinel Lymph Node (SLN) in Melanoma is a procedure that aims the identification of the first node to which the affected cutaneous sector drains in order to avoid unnecessary lymphadenectomies. The present study documents the frequency of identification of SLN; the relationship between positive SLN (PSLN) and recurrence, between the Breslow index (BI) and PSLN, and between BI and disease recurrence.

Method: We analyzed the records of 148 patients with melanoma stages I and II undergoing lymphatic mapping and GC biopsy from 1999 to 2017 in a third level institution in Córdoba, Argentina. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.24875/CIRU.18000439DOI Listing
January 2019
1 Read

Association between tumor-infiltrating lymphocytes and sentinel lymph node positivity in thin melanoma.

An Bras Dermatol 2019 Jan-Feb;94(1):47-51

Service of Dermatology, Hospital de Clínicas de Porto Alegre, Universidade Federal do Rio Grande do Sul, Porto Alegre (RS), Brazil.

Background: Sentinel lymph node biopsy in thin invasive primary cutaneous melanoma (up to 1mm thick) is a controversial subject. The presence of tumor-infiltrating lymphocytes could be a factor to be considered in the decision to perform this procedure.

Objective: To evaluate the association between the presence of tumor-infiltrating lymphocytes and lymph node metastases caused by thin primary cutaneous melanoma. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1590/abd1806-4841.20197414DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6360962PMC
July 2017
1 Read

Trends in Sentinel Lymph Node Biopsy Enactment for Cutaneous Melanoma.

Ann Surg Oncol 2019 Feb 4. Epub 2019 Feb 4.

Department of Pathology, University Medical Centre Utrecht, Utrecht University, Utrecht, The Netherlands.

Background: Over recent years, sentinel lymph node biopsy (SLNB) recommendations in guidelines for cutaneous melanoma have changed considerably. We aimed to assess trends in enactment of SLNB to evaluate to what extent guidelines were adhered to, and to identify clinical and pathological determinants of (non-)adherence.

Methods: Clinicopathological data from the Dutch nationwide network and registry of histopathology and cytopathology were retrieved from patients diagnosed with primary cutaneous melanoma in The Netherlands between 2003 and 2014. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1245/s10434-019-07204-2
Publisher Site
http://dx.doi.org/10.1245/s10434-019-07204-2DOI Listing
February 2019
3 Reads

Postbiopsy Pigmentation is Prognostic in Head and Neck Melanoma.

Ann Surg Oncol 2019 Jan 31. Epub 2019 Jan 31.

Department of Surgery, Gastrointestinal Tumor and Endocrine Surgery, University of Colorado School of Medicine, Aurora, CO, USA.

Purpose: To assess postbiopsy pigmentation (PBP) as a prognostic feature in patients with cutaneous head and neck (H&N) melanoma.

Methods: Retrospective review of patients undergoing sentinel lymph node biopsy (SLNB) for H&N melanoma (1998-2018). PBP was defined as visible remaining pigment at the scar or biopsy site that was documented on physical exam by both a medical oncologist and a surgeon at initial consultation. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1245/s10434-019-07185-2
Publisher Site
http://dx.doi.org/10.1245/s10434-019-07185-2DOI Listing
January 2019
2 Reads

Natural history of pain associated with melanoma surgery.

Pain Rep 2018 Nov 19;3(6):e689. Epub 2018 Oct 19.

California Pacific Medical Center Research Institute, San Francisco, CA, USA.

Introduction: After excision of a primary malignant melanoma (MM), treatment of stage IB or higher MM consists of sentinel lymph node biopsy (SLNB). If malignant cells are identified, a complete lymph node dissection (CLND) can be performed.

Objective: To determine the natural history of pain and sensory changes after MM surgery. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/PR9.0000000000000689DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6344134PMC
November 2018
1 Read

Performance of a 31-gene expression profile test in cutaneous melanomas of the head and neck.

Head Neck 2019 Jan 29. Epub 2019 Jan 29.

Division of Surgical Oncology, Knight Cancer Institute, Oregon Health & Science University, Portland, Oregon.

Background: We report the performance of a gene expression profile test to classify the recurrence risk of cutaneous melanoma tumors of the head and neck as low-risk Class 1 or high-risk Class 2.

Methods: Of note, 157 primary head and neck cutaneous melanoma tumors were identified. Survival analyses were performed using Kaplan-Meier and Cox methods. Read More

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1002/hed.25473
Publisher Site
http://dx.doi.org/10.1002/hed.25473DOI Listing
January 2019
10 Reads

Guidance of sentinel lymph node biopsy decisions in patients with T1-T2 melanoma using gene expression profiling.

Future Oncol 2019 Jan 29. Epub 2019 Jan 29.

Division of Surgical Oncology, Department of Surgery, The University of Tennessee Health Science Center, Memphis, TN 38163, USA.

Aim: Can gene expression profiling be used to identify patients with T1-T2 melanoma at low risk for sentinel lymph node (SLN) positivity?

Patients & Methods: Bioinformatics modeling determined a population in which a 31-gene expression profile test predicted <5% SLN positivity. Multicenter, prospectively-tested (n = 1421) and retrospective (n = 690) cohorts were used for validation and outcomes, respectively.

Results: Patients 55-64 years and ≥65 years with a class 1A (low-risk) profile had SLN positivity rates of 4. Read More

View Article

Download full-text PDF

Source
https://www.futuremedicine.com/doi/10.2217/fon-2018-0912
Publisher Site
http://dx.doi.org/10.2217/fon-2018-0912DOI Listing
January 2019
3 Reads

Should Sentinel Lymph Node Biopsy Be Performed for All T1b Melanomas in the New 8 Edition American Joint Committee on Cancer Staging System?

J Am Coll Surg 2019 Jan 17. Epub 2019 Jan 17.

Hiram C Polk Jr, MD, Department of Surgery, University of Louisville, Louisville, KY.

Background: In the 8 edition of the American Joint Committee on Cancer melanoma staging system, the T1b category has been redefined based solely on thickness and ulceration. National Comprehensive Cancer Network guidelines recommend consideration of sentinel lymph node biopsy (SLNB) for all patients with T1b melanomas (0.8 to 1. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S10727515193004
Publisher Site
http://dx.doi.org/10.1016/j.jamcollsurg.2018.12.030DOI Listing
January 2019
4 Reads

Eye-Sparing Treatment for Diffuse Invasive Conjunctival Melanoma.

Ocul Oncol Pathol 2018 Jun 1;4(4):261-266. Epub 2018 Feb 1.

Department of Ophthalmology, University of Cincinnati College of Medicine, Cincinnati, Ohio, USA.

The management of patients with diffuse invasive conjunctival melanoma focuses on local tumor control and screening for metastasis. Despite the lack of consensus on the benefit of sentinel lymph node biopsy for these neoplasms, the information obtained by histopathology is useful for tumor staging and treatment planning. Due to the lack of evidence of survival improvement, orbital exenteration is being performed with diminishing frequency. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000485978DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6322084PMC
June 2018
1 Read

Clinical implications of the eighth edition of the American Joint Committee on Cancer melanoma staging.

J Surg Oncol 2019 Jan 21;119(2):168-174. Epub 2018 Dec 21.

Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York.

The new edition of the American Joint Committee on Cancer staging system for melanoma builds on the foundation of prior editions but has several important improvements. The availability of regional nodal staging using sentinel lymph node biopsy (with subsequent follow-up) has resulted in more accurate prognostication for patients and clinicians. This facilitates identification of those at higher risk for recurrence, and allows for the appropriate selection of patients for new adjuvant therapy and clinical trials. Read More

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1002/jso.25343
Publisher Site
http://dx.doi.org/10.1002/jso.25343DOI Listing
January 2019
8 Reads

Subungual Melanoma of the Hand.

Ann Surg Oncol 2018 Dec 18. Epub 2018 Dec 18.

Melanoma Institute Australia, Sydney, NSW, Australia.

Background: The diagnosis of subungual melanoma (SUM) can be challenging and SUMs generally have a worse prognosis than melanomas arising elsewhere. Due to their rarity, the evidence to guide management is limited. This study sought to identify clinicopathological features predictive of outcome and to provide guidelines for management. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1245/s10434-018-07094-wDOI Listing
December 2018
1 Read

Current controversies in early-stage melanoma: Questions on incidence, screening, and histologic regression.

J Am Acad Dermatol 2019 01;80(1):1-12

Department of Dermatology, University of Utah Health Sciences Center, Salt Lake City, Utah; Huntsman Cancer Institute, University of Utah Health Sciences Center, Salt Lake City, Utah. Electronic address:

In the first article in this continuing medical education series we review controversies and uncertainties relating to the epidemiology and initial diagnosis of localized cutaneous melanoma (ie, stage 0, I, or II). Many of these issues are unsettled because of conflicting evidence. Melanoma incidence appears to be increasing, yet its basis has not been fully explained. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jaad.2018.03.053DOI Listing
January 2019
10 Reads

Receipt of sentinel lymph node biopsy for thin melanoma is associated with distance traveled for care.

J Surg Oncol 2019 Jan 3;119(1):148-155. Epub 2018 Dec 3.

Department of Surgery, Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire.

Background: Sentinel lymph node biopsy (SLNB) is not routinely recommended for thin melanoma. However, it is considered when high-risk features, clinicopathological, or sociodemographic, are present. It was our objective to evaluate the impact of travel distance on decision-making for SLNB in thin melanoma. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/jso.25314DOI Listing
January 2019
1 Read

Lack of survival benefit in sentinel lymph node-positive melanoma with immediate complete lymphadenectomy - a review.

J Dtsch Dermatol Ges 2019 Jan 3;17(1):7-13. Epub 2018 Dec 3.

Centre for Dermato-oncology, University Department of Dermatology, Eberhard Karls University, Tübingen, Germany.

For decades, melanoma surgery has been guided by the Halstedian concept of stepwise metastasis, first into the lymph nodes and subsequently to distant sites. Early complete lymph node dissection (CLND) was therefore recommended in order to improve survival. Four large prospective randomized trials failed to show any survival benefit of CLND in comparison to observation alone. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/ddg.13707DOI Listing
January 2019
1 Read

Consecutive Case Series of Melanoma Sentinel Node Biopsy for Lymphoseek Compared to Sulfur Colloids.

J Surg Res 2019 Jan 23;233:149-153. Epub 2018 Aug 23.

Department of Surgery, Sidney Kimmel Medical College, Thomas Jefferson University, Surgery, Philadelphia, Pennsylvania. Electronic address:

Background: Sentinel lymph node biopsy (SLNB) is an important adjunct in the staging of patients with melanoma. Preoperative lymphoscintigraphy with radiolabeled isotopes is essential to localize sentinel nodes for removal. Our study compared the effectiveness of Lymphoseek to standard sulfur colloids in patients with melanoma undergoing SLNB. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jss.2018.07.042DOI Listing
January 2019
11 Reads

Management Decisions Made by Physician Assistants and Nurse Practitioners in Cutaneous Malignant Melanoma Patients: Impact of a 31-Gene Expression Profile Test

J Drugs Dermatol 2018 Nov;17(11):1220-1223

Importance: The 31 gene-expression profiling test (31-GEP) has been shown to provide useful prognostic information in patients with cutaneous melanoma. The test dichotomizes patients into lower risk (Class 1) or higher risk (Class 2) for melanoma metastasis. Previous studies have demonstrated the clinical utility of the test in impacting dermatologists’ management decisions. Read More

View Article

Download full-text PDF

Source
November 2018
10 Reads

Management of Regional Lymph Nodes in Patients with Merkel Cell Carcinoma Following a Positive Sentinel Node Biopsy: Less May be More, But is Either Enough?

Ann Surg Oncol 2019 Feb 27;26(2):315-317. Epub 2018 Nov 27.

Faculty of Medicine and Health Sciences, The University of Sydney, Sydney, NSW, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1245/s10434-018-7076-3DOI Listing
February 2019
1 Read

Current management of regional lymph nodes in patients with melanoma.

J Surg Oncol 2019 Jan 27;119(2):200-207. Epub 2018 Nov 27.

Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY.

The publication of recent randomized trials has prompted a significant shift in both our understanding and the management of patients with melanoma. Here, the current management of the regional lymph nodes in patients with melanoma is discussed. This review focuses on selection for sentinel lymph node biopsy, management of the positive sentinel node, management of the clinically positive node, and the controversy over the therapeutic value of early nodal intervention. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/jso.25316DOI Listing
January 2019
1 Read

Time to reconsider the role of sentinel lymph node biopsy in melanoma.

J Am Acad Dermatol 2018 Nov 22. Epub 2018 Nov 22.

Carol Davila University of Medicine and Pharmacy, Bucharest, Romania.

The Multicenter Selective Lymphadenectomy Trials indicate that there are no overall or melanoma-specific survival advantages to performing sentinel lymph node biopsy (SLNB) followed by immediate completion lymph node dissection compared with wide excision and observation for patients with positive sentinel nodes. These results make SLNB solely a staging procedure. The role of SLNB in the management of patients with melanoma deserves reappraisal. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S01909622183295
Publisher Site
http://dx.doi.org/10.1016/j.jaad.2018.11.026DOI Listing
November 2018
11 Reads

Defective levels of both circulating dendritic cells and T-regulatory cells correlate with risk of recurrence in cutaneous melanoma.

Clin Transl Oncol 2018 Nov 23. Epub 2018 Nov 23.

Section of Oncology, Department of Biomedical Sciences and Clinical Oncology, University of Bari 'Aldo Moro', P.za Giulio Cesare, 11, 70124, Bari, Italy.

Background: Immune markers in the peripheral blood of melanoma patients provide useful information for clinical management although there is poor consensus on circulating cells which could putatively reflect the disease activity and play a prognostic role. Here, we investigated both dendritic cells (DCs) and T-regulatory cells (Tregs).

Methods: The number of DC subsets as myeloid (m) and plasmacytoid was measured by flowcytometry in 113 melanoma patients in different clinical stages and correlated with the disease activity to evaluate the recurrence free survival (RFS) calculated as difference between baseline and post-surgical values in relation to the criteria for the melanoma staging, as primary tumor removal, sentinel lymph node biopsy and completion of lymph node dissection. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s12094-018-1993-2DOI Listing
November 2018
8 Reads

Clinical features and outcomes of spitzoid proliferations in children and adolescents.

Br J Dermatol 2018 Nov 22. Epub 2018 Nov 22.

Harvard Medical School, Boston, MA, 02115, U.S.A.

Background: Spitzoid proliferations range from Spitz naevi to melanomas. There are few studies describing clinical features and outcomes in the paediatric population.

Objectives: To determine the clinical features and outcomes of a large paediatric cohort with histopathologically confirmed Spitz tumours. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bjd.17450DOI Listing
November 2018
7 Reads

Validation of a Nomogram for Non-sentinel Node Positivity in Melanoma Patients, and Its Clinical Implications: A Brazilian-Dutch Study.

Ann Surg Oncol 2019 Feb 19;26(2):395-405. Epub 2018 Nov 19.

Department of Surgical Oncology, The Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands.

Background: Non-sentinel node (NSN) positivity impacts the prognosis of melanoma patients; however, the benefits of completion lymph node dissection in patients with positive sentinel nodes (SNs) are limited.

Objective: We aimed to present a predictive nomogram for NSN positivity in melanoma patients with a positive SN biopsy.

Methods: This retrospective analysis from patients who underwent SN biopsy in a Brazilian institution from 2000 to 2015 was used for the construction and internal validation of the nomogram. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1245/s10434-018-7038-9DOI Listing
February 2019
10 Reads

Sentinel lymph node imaging in urologic oncology.

Transl Androl Urol 2018 Oct;7(5):887-902

Molecular Imaging Program, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.

Lymph node (LN) metastases in urological malignancies correlate with poor oncological outcomes. Accurate LN staging is of great importance since patients can benefit from an optimal staging, accordingly aligned therapy and more radical treatments. Current conventional cross-sectional imaging modalities [e. Read More

View Article

Download full-text PDF

Source
http://tau.amegroups.com/article/view/21133/21414
Publisher Site
http://dx.doi.org/10.21037/tau.2018.08.23DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6212622PMC
October 2018
22 Reads

Prognostic impact of regression in patients with primary cutaneous melanoma >1 mm in thickness.

J Am Acad Dermatol 2019 Jan 14;80(1):99-105.e5. Epub 2018 Nov 14.

Unit of Medical Oncology, Papa Giovanni XXIII Hospital, Bergamo, Italy. Electronic address:

Background: The impact of histologic regression on sentinel lymph node biopsy (SLNB) status and on clinical outcome is uncertain.

Objective: To investigate whether and to what extent regression <75% is able to predict SLNB status and clinical outcome of patients with melanoma >1-mm thick.

Methods: The study included patients with diagnoses given at 4 centers of the Italian Melanoma Intergroup. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S01909622183221
Publisher Site
http://dx.doi.org/10.1016/j.jaad.2018.06.054DOI Listing
January 2019
12 Reads
4.450 Impact Factor

Microsatellitosis in Patients with Melanoma.

Ann Surg Oncol 2019 Jan 12;26(1):33-41. Epub 2018 Nov 12.

Moffitt Cancer Center, Tampa, FL, USA.

Background: Microsatellitosis (mS) in melanoma has been considered a marker of unfavorable tumor biology, leading to the current American Joint Committee on Cancer staging of IIIB/C/D disease, despite few investigative studies of this entity limited by the small sample sizes and incomplete nodal microstaging. We sought to better characterize outcomes and prognostic factors in a multi-institutional cohort of patients with mS and nodal microstaging.

Methods: The Sentinel Lymph Node Working Group cohort included 414 mS patients who underwent sentinel lymph node (SLN) biopsy. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1245/s10434-018-7006-4DOI Listing
January 2019
27 Reads

The long-term prognostic impact of sentinel lymph node biopsy in patients with primary cutaneous melanoma: a prospective study with 10-year follow-up.

Ann Surg Treat Res 2018 Nov 25;95(5):286-296. Epub 2018 Oct 25.

Department of Surgery and Department of Morphology, Surgery and Experimental Medicine, S. Anna University Hospital and University of Ferrara, Ferrara, Italy.

Purpose: Sentinel lymph node (SLN) biopsy (SLNB) is widely accepted for staging of melanoma patients. It has been shown that clinico-pathological features such as Breslow thickness, ulceration, age, and sex are better predictors of relapse and survival than SLN status alone. The aims of this study were to evaluate the long-term (10-year) prognostic impact of SLNB and to determine predictive factors associated with SLN metastasis, relapse, and melanoma specific mortality (MSM). Read More

View Article

Download full-text PDF

Source
https://synapse.koreamed.org/DOIx.php?id=10.4174/astr.2018.9
Publisher Site
http://dx.doi.org/10.4174/astr.2018.95.5.286DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6204324PMC
November 2018
12 Reads

Risk Factors for Regional and Systemic Metastases in Patients with Sentinel Lymph Node-negative Melanoma.

Anticancer Res 2018 Nov;38(11):6571-6577

Department of Surgery, University Hospital Erlangen, Friedrich Alexander University Erlangen-Nürnberg (FAU), Erlangen, Germany.

Background: Sentinel lymph node status is a strong prognostic factor in melanoma. However, up to 21% of sentinel lymph node-negative patients develop locoregional and distant metastases during follow-up.

Aim: To analyze risk factors for locoregional and distant metastasis in patients with sentinel lymph node-negative melanoma. Read More

View Article

Download full-text PDF

Source
http://ar.iiarjournals.org/lookup/doi/10.21873/anticanres.13
Publisher Site
http://dx.doi.org/10.21873/anticanres.13024DOI Listing
November 2018
11 Reads

A nomogram to identify high-risk melanoma patients with a negative sentinel lymph node biopsy.

J Am Acad Dermatol 2019 Mar 2;80(3):722-726. Epub 2018 Nov 2.

Skin Cancer Department, AC Camargo Cancer Center, São Paulo, Brazil.

Background: Melanoma patients with negative nodes after sentinel lymph node biopsy are a heterogeneous group. Current guidelines fail to adequately stratify surveillance and treatment for this group. Also, there is scarce data on adjuvant treatments for these patients. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jaad.2018.10.060DOI Listing
March 2019
14 Reads

Guidelines of care for the management of primary cutaneous melanoma.

J Am Acad Dermatol 2019 01 1;80(1):208-250. Epub 2018 Nov 1.

American Academy of Dermatology, Rosemont, Illinois.

The incidence of primary cutaneous melanoma continues to increase each year. Melanoma accounts for the majority of skin cancer-related deaths, but treatment is usually curative following early detection of disease. In this American Academy of Dermatology clinical practice guideline, updated treatment recommendations are provided for patients with primary cutaneous melanoma (American Joint Committee on Cancer stages 0-IIC and pathologic stage III by virtue of a positive sentinel lymph node biopsy). Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S01909622183258
Publisher Site
http://dx.doi.org/10.1016/j.jaad.2018.08.055DOI Listing
January 2019
15 Reads

Inter-observer variation in the histopathology reports of head and neck melanoma; a comparison between the seventh and eighth edition of the AJCC staging system.

Eur J Surg Oncol 2019 02 25;45(2):235-241. Epub 2018 Oct 25.

Department of Head and Neck Surgery and Oncology at the Netherlands Cancer Institute-Antoni van Leeuwenhoek, Plesmanlaan 121, NL-1066 CX Amsterdam, the Netherlands. Electronic address:

Background: TNM staging of melanoma has recently been altered by the introduction of the 8th edition of the AJCC Cancer Staging manual. The purpose of this study is to analyze the inter-observer variation of histopathology reports and its effect on recommended treatment policy.

Methods: We retrospectively analyzed 296 cases, diagnosed as primary cutaneous head and neck melanoma (2005-2016), referred to the Netherlands Cancer Institute (NCI) for treatment after prior diagnosis in another hospital (non-NCI). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejso.2018.10.529DOI Listing
February 2019
1 Read

Sentinel Lymph Node Biopsy: Past and Present Implications for the Management of Cutaneous Melanoma with Nodal Metastasis.

Authors:
Abel Gonzalez

Am J Clin Dermatol 2018 Nov;19(Suppl 1):24-30

Mohs Surgery Unit, Institute of Oncology Angel H. Roffo, University of Buenos Aires, Av San Martin 5481, Ciudad Autónoma de Buenos Aires, Buenos Aires, Argentina.

Although significant progress has been made in the understanding of melanoma pathophysiology and therapy, patients with metastatic melanoma still have a poor prognosis. The management of regional nodes remains a matter of debate. By replacing elective lymph node dissection, sentinel lymph node biopsy has revolutionized the treatment of malignant melanoma. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s40257-018-0379-0
Publisher Site
http://dx.doi.org/10.1007/s40257-018-0379-0DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6244615PMC
November 2018
6 Reads

Long Term Cosmetic and Functional Results of One Stage Reconstruction for Lower Eyelid Malignant Melanoma: A Single Centre Experience of Eleven Patients.

J Maxillofac Oral Surg 2018 Dec 30;17(4):625-629. Epub 2016 Jun 30.

2ENT Department, S. Orsola Malpighi University Hospital, Bologna, Italy.

Introduction: Eyelid malignant melanoma represents less than 1 % of all skin melanomas and approximately 1 % of all malignant neoplasms of the eyelid skin. Because of its relative rarity, there is a paucity of descriptive papers reporting only small series of reconstructed patients. The repair of eyelid defects represents a reconstructive challenge. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s12663-016-0932-4
Publisher Site
http://dx.doi.org/10.1007/s12663-016-0932-4DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6181842PMC
December 2018
9 Reads

Failure to identify sentinel lymph nodes for malignant melanoma - Outcome after over 10 years median follow up.

Eur J Surg Oncol 2019 02 16;45(2):231-234. Epub 2018 Oct 16.

Department of Surgery, Rabin Medical Center, Petah Tikva, Israel; The Sackler School of Medicine, Tel-Aviv University, Israel.

Background: Sentinel lymph node biopsy (SLNB) is routinely performed during surgery for malignant melanoma, using double mapping. Still, in some cases, a sentinel lymph node identified pre-operatively by lymphoscintigraphy is not identified during surgery. We hypothesized that disease specific survival would not be significantly impacted by intra-operative lymph node mapping (IOLM) failure. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S07487983183142
Publisher Site
http://dx.doi.org/10.1016/j.ejso.2018.09.010DOI Listing
February 2019
14 Reads

Survival outcomes and interval between lymphoscintigraphy and SLNB in cutaneous melanoma- findings of a large prospective cohort study.

Eur J Surg Oncol 2018 11 23;44(11):1768-1772. Epub 2018 Jun 23.

Department of Plastic & Reconstructive Surgery, Norfolk and Norwich University Hospitals NHS Foundation Trust, Colney Lane, Norwich, Norfolk, NR4 7UY, UK; Norwich Medical School, University of East Anglia Norwich Research Park, Norwich, NR4 7TJ, UK.

Introduction: Sentinel lymph node biopsy (SLNB) in cutaneous melanoma (CM) is performed to identify patient at risk of regional and distant relapse. We hypothesized that timing of lymphoscintigraphy may influence the accuracy of SLNB and patient outcomes.

Methods: We reviewed prospective data on patients undergoing SLNB for CM at a large university cancer-center between 2008 and 2015, examining patient and tumor demographics and time between lymphoscintigraphy (LS) and SLNB. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejso.2018.06.011DOI Listing
November 2018
3 Reads

SMAD7 is a novel independent predictor of survival in patients with cutaneous melanoma.

Transl Res 2019 Feb 27;204:72-81. Epub 2018 Sep 27.

Department of Pathomorphology and Oncological Cytology, Wroclaw Medical University, Wroclaw, Poland.

Overexpression of SMAD7-a hallmark inhibitor of transforming growth factor β (TGFβ) signaling-has been documented and related with adverse prognosis in a number of epithelial malignancies, suggesting that it may be responsible for resistance to TGFβ-induced growth arrest of cancer cells. The involvement of SMAD7 in development and progression of malignant melanoma is unclear, and its expression has not been characterized so far at the protein level in clinical melanoma tissue samples. We evaluated SMAD7 expression in 205 skin melanoma primary tumors by immunohistochemistry and correlated the findings with clinicopathological profiles of patients. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S19315244183017
Publisher Site
http://dx.doi.org/10.1016/j.trsl.2018.09.002DOI Listing
February 2019
9 Reads

Development and validation of a nomogram to predict recurrence and melanoma-specific mortality in patients with negative sentinel lymph nodes.

Br J Surg 2019 Feb 11;106(3):217-225. Epub 2018 Oct 11.

Department of Surgical Oncology, Erasmus MC Cancer Institute, University Medical Centre, Rotterdam, the Netherlands.

Background: Patients with melanoma and negative sentinel nodes (SNs) have varying outcomes, dependent on several prognostic factors. Considering all these factors in a prediction model might aid in identifying patients who could benefit from a personalized treatment strategy. The objective was to construct and validate a nomogram for recurrence and melanoma-specific mortality (MSM) in patients with melanoma and negative SNs. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/bjs.10995DOI Listing
February 2019

ASO Author Reflections: Factors that Predict Performance of Sentinel Lymph Node Biopsy and the Association with Improved Survival for Melanoma Patients Who Have Nodal Staging.

Ann Surg Oncol 2018 Dec 9;25(Suppl 3):904-905. Epub 2018 Oct 9.

Division of Surgical Oncology, Department of Surgery, Oregon Health and Science University, Portland, OR, USA.

View Article

Download full-text PDF

Source
http://link.springer.com/10.1245/s10434-018-6841-7
Publisher Site
http://dx.doi.org/10.1245/s10434-018-6841-7DOI Listing
December 2018
3 Reads

Sentinel lymph node biopsy remains the most accurate method of obtaining staging and prognostic information for patients with primary cutaneous melanomas.

Australas J Dermatol 2019 Feb 7;60(1):75-76. Epub 2018 Oct 7.

Melanoma Institute Australia, The University of Sydney, Sydney, New South Wales, Australia.

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1111/ajd.12942
Publisher Site
http://dx.doi.org/10.1111/ajd.12942DOI Listing
February 2019
2 Reads

The Role of Completion Lymph Node Dissection for Sentinel Lymph Node-Positive Melanoma.

Ann Surg Oncol 2018 Oct 3. Epub 2018 Oct 3.

Department of Surgery, Geisel School of Medicine at Dartmouth, Hanover, NH, USA.

Purpose And Methods: Completion lymph node dissection (CLND) for sentinel lymph node (SLN)-positive melanoma patients has been guideline-concordant standard of care since adoption of lymphatic mapping and SLN biopsy for the management of clinically node-negative melanoma patients more than 20 years ago. However, a trend for omission of CLND has been observed over the past decade, and we now have randomized, controlled clinical trial data to help guide treatment recommendations. Publication of these data prompted an American Society of Clinical Oncology-Society of Surgical Oncology 2018 clinical practice guideline update for these patients. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1245/s10434-018-6812-zDOI Listing
October 2018

Age-Related Changes in HAPLN1 Increase Lymphatic Permeability and Affect Routes of Melanoma Metastasis.

Cancer Discov 2019 Jan 2;9(1):82-95. Epub 2018 Oct 2.

The Wistar Institute, Philadelphia, Pennsylvania.

: Older patients with melanoma have lower rates of sentinel lymph node (LN) metastases yet paradoxically have inferior survival. Patient age correlated with an inability to retain Technetium radiotracer during sentinel LN biopsy in more than 1,000 patients, and high Technetium counts correlated to better survival. We hypothesized that loss of integrity in the lymphatic vasculature due to extracellular matrix (ECM) degradation might play a role. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/2159-8290.CD-18-0168DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6328344PMC
January 2019
18 Reads
15.930 Impact Factor

A model for predicting low probability of nonsentinel lymph node positivity in melanoma patients with a single positive sentinel lymph node.

J Surg Oncol 2018 Nov 27;118(6):922-927. Epub 2018 Sep 27.

Department of Surgery, University of Louisville, Louisville, Kentucky.

Background: Identifying factors associated with nonsentinel lymph node (NSN) metastases in melanoma patients with a single positive sentinel lymph node (SLN) could aid decision making regarding adjuvant therapy. We describe a model for identifying patients with a single positive SLN at low risk for NSN metastasis.

Methods: Factors associated with NSN metastasis in patients with a primary cutaneous melanoma and a single positive SLN who underwent completion lymph node dissection (CLND) were identified. Read More

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1002/jso.25193
Publisher Site
http://dx.doi.org/10.1002/jso.25193DOI Listing
November 2018
8 Reads

Cartilage-sparing surgery for melanoma of the external ear.

J Plast Reconstr Aesthet Surg 2019 Jan 4;72(1):92-96. Epub 2018 Sep 4.

Blenheim Head and Neck Unit, Churchill Hospital, Old Road, Headington, Oxford, OX3 7LE, UK.

Background: The excision of melanoma of the external ear poses a challenge to surgeons, who must achieve adequate oncological control while minimising impact on form and function. Cartilage-preserving surgery is an attractive option, as it leaves behind a scaffold for immediate reconstruction with a variety of techniques including full-thickness skin grafts (FTSGs) and local flaps. This manuscript will review the literature comparing cartilage-sparing surgery with composite excision of the skin and the cartilage for the treatment of auricular melanoma. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bjps.2018.08.028DOI Listing
January 2019
7 Reads

Predictors of sentinel lymph node positivity in thin melanoma using the National Cancer Database.

J Am Acad Dermatol 2019 Feb 18;80(2):441-447. Epub 2018 Sep 18.

Department of Dermatology and Plastic Surgery, Cleveland Clinic, Cleveland, Ohio. Electronic address:

Background: Sentinel lymph node biopsy (SLNB) specimens are often obtained from patients for further staging after these patients have undergone melanoma excision. Limited data regarding predictors of SLNB positivity in thin melanoma are available.

Objective: We sought to evaluate predictors of SLNB positivity in thin melanoma. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jaad.2018.08.051DOI Listing
February 2019
4 Reads

Sentinel Lymph Node Biopsy and Completion Lymph Node Dissection for Melanoma.

Curr Treat Options Oncol 2018 Sep 19;19(11):55. Epub 2018 Sep 19.

Department of Surgery, Duke University, Durham, NC, 27710, USA.

Opinion Statement: This review critically evaluates recent trials which have challenged the practice of completion lymph node dissection (CLND) for melanoma patients diagnosed with regional metastasis by positive sentinel lymph node biopsy (SLNB). Two trials in the last 2 years, DeCOG-SLT and MSLT-II, found no significant differences in melanoma-specific survival between patients, whether they received immediate CLND or observation after positive SLNB, despite decreases in nodal recurrence achieved by dissection. These trials together disfavor routine CLND in most patients after positive SLNB. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11864-018-0575-4DOI Listing
September 2018
5 Reads

Practice-Changing Developments in Stage III Melanoma: Surgery, Adjuvant Targeted Therapy, and Immunotherapy.

Am Soc Clin Oncol Educ Book 2018 May(38):759-762

From the Department of Hematology/Oncology, Winship Cancer Institute, Emory University, Atlanta, GA; Department of Oncology, Lausanne University Hospital, Lausanne, Switzerland; Department of Surgical Oncology, Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, Amsterdam, Netherlands.

In this article, we will focus on the practice-changing developments for stage III melanoma, from the use of the sentinel node (SN) biopsy to complete lymph node dissection (CLND) and upcoming adjuvant therapies. MSLT-1 (Multicenter Selective Lymphadenectomy Trial-1) was the first and only prospective randomized controlled trial to examine whether the SN biopsy has any notable melanoma-specific survival benefit (primary endpoint). MSLT-1 randomly assigned 2,001 patients to undergo either wide local excision (WLE) and an SN biopsy or WLE and nodal observation. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/EDBK_200241DOI Listing

Predicting risk for seroma development after axillary or inguinal sentinel lymph node biopsy in melanoma patients.

Int J Dermatol 2019 Feb 19;58(2):185-189. Epub 2018 Sep 19.

Department of Dermatology and Venereology, University Hospital of Cologne, Cologne, Germany.

Background: Sentinel lymph node biopsy (SLNB) is currently a routine procedure in the staging of patients with cutaneous melanoma; however, little information is available about the risk factors for postoperative complications, especially for the risk of seroma formation.

Methods: Medical records of patients undergoing SLNB at the University Hospital of Cologne, Germany, between 2011 and 2016, were reviewed. Binary logistic regression was used to analyze the influence of a wide range of variables on seroma development. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/ijd.14247DOI Listing
February 2019
2 Reads

Sentinel lymph node biopsy in patients with thin melanomas: Frequency and predictors of metastasis based on analysis of two large international cohorts.

J Surg Oncol 2018 Sep 9;118(4):599-605. Epub 2018 Sep 9.

Department of Clinical Sciences Lund, Surgery, Lund University, Skåne University Hospital, Lund, Sweden.

Background: Sentinel lymph node (SLN) metastasis in patients with thin melanomas (≤1 mm) is uncommon but adverse prognostic factors may indicate an increased risk. We sought to determine how often SLN biopsy (SLNB) was performed in patients with thin melanomas, establish the frequency of SLN metastasis and evaluate the predictive value of ulceration, tumor mitotic rate, and thickness for SLN involvement.

Methods: Melanoma patients with a Breslow thickness greater than or equal to 0. Read More

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1002/jso.25208
Publisher Site
http://dx.doi.org/10.1002/jso.25208DOI Listing
September 2018
10 Reads

Interferon is associated with improved survival for node-positive cutaneous melanoma: a single-institution experience.

Melanoma Manag 2018 Jun 9;5(1):MMT02. Epub 2018 Apr 9.

Department of Radiation Oncology, Moffitt Cancer Center, Tampa, FL 33612, USA.

Aim: We assessed the role of adjuvant interferon on relapse-free survival (RFS), distant metastasis-free survival (DMFS) and overall survival (OS) in node-positive melanoma patients.

Methods: We retrospectively reviewed 385 node-positive patients without distant metastatic disease treated from 1998 to 2015. The surgery was therapeutic lymph node dissection (LND, n = 86) or sentinel lymph node biopsy ± completion LND (n = 270). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/mmt-2017-0025DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6122528PMC
June 2018
2 Reads

Predictive genetic profiles for regional lymph node metastasis in primary cutaneous melanoma: a case-matched pilot study.

Melanoma Res 2018 12;28(6):555-561

Department of Surgery, Greenville Health System.

Melanoma confers an estimated lifetime risk of one in 50 for 2016. Clinicopathologic staging and sentinel lymph node biopsy (SLNB) have been the standard of care for T2 and T3 lesions. Molecular biomarkers identified in the primary lesion suggestive of metastatic potential may offer a more conclusive prognosis of these lesions. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/CMR.0000000000000499DOI Listing
December 2018
4 Reads